Skip to main content
SpringerLink
Log in

Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson’s Disease, and Levodopa Efficacy

  • Original Research Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

Objectives

We investigated the association between catechol-O-methyltransferase (COMT) gene polymorphisms and Parkinson’s disease (PD) susceptibility, severity of disease, and levodopa (l-Dopa) efficacy.

Subjects and Methods

Patients (N = 97) with primary PD and healthy volunteers (N = 102) were recruited. Disease severity was assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn & Yahr grade at ‘On stage’. Genomic DNA was extracted from blood cells. Polymerase chain reaction and sequencing were used to detect COMT mutations. Data were analyzed by SPSS 18.0. False discovery rate (FDR) or Bonferroni correction was used if the result showed P < 0.05.

Results

Four COMT mutations were detected in 199 subjects: rs74745580 (only in two patients with primary PD), rs4633, rs6267, and rs3838146. There were no statistical differences in frequencies of rs4633, rs6267, and rs3838146 genotypes between PD patients and the control group. The frequency of allele rs4633T was higher in PD patients than in the control group. UPDRS score was lower in rs4633 (CT/TT) carriers and rs3838146 (–C/– –) carriers than in rs4633 (CC) and rs3838146 (CC) carriers. PD patients carrying rs6267 (GT/TT) had higher UPDRS scores than patients with rs6267 (GG) (P < 0.05). The frequencies of the three polymorphisms were not statistically different between patients who did and did not receive l-Dopa; dose and duration of l-Dopa treatment did not differ between genotypes; and there was also no difference in the ratios of loss of efficacy towards levodopa.

Conclusions

The polymorphisms rs4633, rs6267, and rs3838146 were associated with severity of PD but were not associated with l-Dopa medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123(11):2297–305.

    Article  PubMed  Google Scholar 

  2. Garcia Ruiz PJ, Meseguer E, Del Val J, et al. Motor complications in Parkinson disease: a prospective follow-up study. Clin Neuropharmacol. 2004;27(2):49–52.

    Google Scholar 

  3. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756–60.

    Article  PubMed  Google Scholar 

  4. Thanvi BR, Lo TC. Long term motor complications of levodopa: clinical features, mechanisms and management strategies. Postgrad Med J. 2004;80(5):452–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Woitalla D, Karwasz R, Müller T, et al. The activity of catechol-O-methyltransferase in parkinsonian patients with “on–off fluctuations”. J Neural Transm. 2000;107(1):105–11.

    Article  CAS  PubMed  Google Scholar 

  6. Poewe WH, Deuschl G, Gordin A, et al., Celomen Study Group. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245–55.

    Google Scholar 

  7. Poulopoulos M, Waters C. Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease. Core Evid. 2010;27(5):1–10.

    Google Scholar 

  8. Hamaue N, Ogata A, Terado M, et al. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson’s disease induced by Japanese encephalitis virus. Brain Res. 2010;14(1309):110–5.

    Article  Google Scholar 

  9. Bray NJ, Buckland PR, Williams NM, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet. 2003;73:152–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525–8.

    Article  CAS  PubMed  Google Scholar 

  11. Tai CH, Wu RM. Catechol-O-methyltransferase and Parkinson’s disease. Acta Med Okayama. 2002;56(1):1–6.

    CAS  PubMed  Google Scholar 

  12. Bialecka M, Kurzawski M, Klodowska-Duda G, et al. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson’s disease, levodopa treatment response, and complications. Pharmacogenet Genomics. 2008;18(9):815–21.

    Article  CAS  PubMed  Google Scholar 

  13. Kalinderi K, Fidani L, Kourtesi G, et al. No association of the Val158Met COMT polymorphism with Parkinson’s disease in the Greek population. Eur J Neurol. 2008;15:e83.

    Article  CAS  PubMed  Google Scholar 

  14. Hoda F, Nicholl D, Bennett P, et al. No association between Parkinson’s disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun. 1996;228:780–4.

    Article  CAS  PubMed  Google Scholar 

  15. Williams-Gray CH, Hampshire A, Barker RA, et al. Attentional control in Parkinson’s disease is dependent on COMT val 158 met genotype. Brain. 2008;131:397–408.

    Article  PubMed  Google Scholar 

  16. Wu K, O’Keeffe D, Politis M, et al. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson’s disease: a PET study. Brain. 2012;135:2449–57.

    Article  PubMed  Google Scholar 

  17. de Lau LM, Verbaan D, Marinus J, et al. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord. 2012;27:132–5.

    Article  PubMed  Google Scholar 

  18. Antonini A, Martinez-Martin P, Chaudhuri RK, et al. Wearing-off scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(12):2169–75.

    Article  PubMed  Google Scholar 

  19. Warren Olanow C, Kieburtz K, Rascol O, et al., Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) Investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–71.

    Google Scholar 

  20. Kunugi H, Nanko S, Ueki A, et al. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson’s disease. Neurosci Lett. 1997;221(2–3):202–4.

    Article  CAS  PubMed  Google Scholar 

  21. Białecka M, Kurzawski M, Roszmann A, et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s disease. Pharmacogenet Genomics. 2012;22:716–24.

    Article  PubMed  Google Scholar 

  22. Nackley AG, Shabalina SA, Lambert JE, et al. Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs. PLoS One. 2009;4:e5237.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Białecka M, Droździk M, Kłodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson’s disease. Acta Neurol Scand. 2004;110:260–6.

    Article  PubMed  Google Scholar 

  24. Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson’s disease: a randomized crossover clinical trial. Ann Neurol. 2011;69(1):111–8.

    Article  CAS  PubMed  Google Scholar 

  25. Watanabe M, Harada S, Nakamura T, et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson’s disease. Neuropsychobiology. 2003;48:190–3.

    Article  CAS  PubMed  Google Scholar 

  26. Chong DJ, Suchowersky O, Szumlanski C, et al. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson’s disease. Clin Neuropharmacol. 2000;23(3):143–8.

    Google Scholar 

  27. Contin M, Martinelli P, Mochi M, et al. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson’s disease. Mov Disord. 2005;20(6):734–9.

    Article  PubMed  Google Scholar 

  28. Lee MS, Lyoo CH, Ulmanen I, et al. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson’s disease. Neurosci Lett. 2001;298(2):131–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments and Disclosures

This work was supported by the Promoting Foundation of Doctor of the 2nd Hospital of Harbin Medical University. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Department of Neurology, Second Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, People’s Republic of China

    Bowen Yin, Yongqian Chen & Limei Zhang

Authors
  1. Bowen Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongqian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Limei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Limei Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yin, B., Chen, Y. & Zhang, L. Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson’s Disease, and Levodopa Efficacy. Mol Diagn Ther 18, 253–260 (2014). https://doi.org/10.1007/s40291-013-0066-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-013-0066-z

Keywords

Search

Navigation